|
|||||||||||||||||||||||||||||||||||||||||||||||
|
Multiple Sclerosis Info
Favorite Links
This Month
Month Archive
|
Friday, April 11
MS Therapies - Betaseron
by
All About MS
on Fri 11 Apr 2008 12:00 AM CST
Interferon beta-1b belongs to a class of medications known as immunomodulators. It is used to reduce the frequency of exacerbations (worsening of symptoms) in people suffering with relapsing-remitting multiple sclerosis.
Multiple sclerosis (MS) is caused by more »
Wednesday, March 19
Rash from interferon beta 1-a (Rebif or Betaseron)
by
All About MS
on Wed 19 Mar 2008 02:00 AM CST
We describe a 41-year-old woman with multiple sclerosis, who presented with redness of the skin; several discoloured areas; along with inflammatory small, more »
Tuesday, February 26
Predictive markers for response to interferon therapy in patients with multiple sclerosis.
by
All About MS
on Tue 26 Feb 2008 12:00 AM CST
Prolonged therapy with interferon beta (IFNbeta) often leads to the development of anti-IFNbeta binding antibodies (BAbs). A subset of the BAbs is of a neutralizing nature (neutralizing antibodies, NAbs) and more »
Wednesday, February 6
Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
by
All About MS
on Wed 06 Feb 2008 06:57 AM CST
Biogen Idec Inc. and PDL BioPharma, Inc. (PDL) announced
that Phase 2 data demonstrated a significant reduction in new or enlarged gadolinium- enhancing lesions when daclizumab more »
Tuesday, February 5
A Controlled Trial of Tysabri (Natalizumab) for Relapsing Multiple Sclerosis
by
All About MS
on Tue 05 Feb 2008 08:15 AM CST
The glycoprotein integrin is expressed on the surface of these cells and plays a critical part in their adhesion to the vascular endothelium and migration into the parenchyma. Tysabri (Natalizumab) is an integrin antagonist that reduced the development of brain lesions in more »
Monday, February 4
FDA Approves Betaseron for Use After the First Event Suggestive of Multiple Sclerosis
by
All About MS
on Mon 04 Feb 2008 07:20 AM CST
The two-year study showed that treatment with Betaseron delayed the time to a second clinical event by one year compared to placebo. (1) BENEFIT is the only trial to demonstrate the more »
Monday, December 31
Interferon Beta-1b Delays Development of MS
by
All About MS
on Mon 31 Dec 2007 09:07 AM CST
BENEFIT Study Shows Interferon Beta-1b Delays Development of MS in Patients with First Clinical Signs of Disease BASEL, SWITZERLAND -- October 14, 2005 – Interferon beta-1b 250 mcg* ... more » Thursday, December 13
Early Treatment With Betaseron Significantly Delayed the Time to a Second Clinical Event
by
All About MS
on Thu 13 Dec 2007 09:23 AM CST
Using interferon beta-1b (Betaseron) therapy in patients with the first clinical symptoms of MS (MS) significantly postpones the development of more »
Patients Treated With Betaseron(R) After First MS Attack
by
All About MS
on Thu 13 Dec 2007 04:09 AM CST
Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression WAYNE, N.J., Wednesday, November 28
New natural history of interferon-beta-treated RRMS
by
All About MS
on Wed 28 Nov 2007 12:00 AM CST
New natural history of interferon-beta-treated relapsing multiple sclerosis. Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy. To investigate the impact ... more » |
||||||||||||||||||||||||||||||||||||||||||||||
